On July 23, 2026, the EU ECHA issued its latest notice, adding L-cystine, L-tyrosine, and DL-leucine to the 29th batch of the SVHC Candidate List. For trade with the EU involving the relevant substances, this is not merely an adjustment to the list; it also means that supply-chain information communication and SCIP notification obligations will take effect simultaneously. From August 1, 2026, if the concentration of any of the above substances in imported articles reaches or exceeds 0.1%, the relevant parties will need to complete SCIP registration. For Chinese amino acid exporters and their upstream and downstream customers, product identification, document preparation, delivery arrangements, and customer communication will all enter a more urgent compliance cycle.

Compliance requirements clarified in this list adjustment

According to the information provided, the EU ECHA issued a notice on its official website on July 23, 2026, formally adding L-cystine, L-tyrosine, and DL-leucine to the SVHC Candidate List (29th batch). This change directly triggers supply-chain information communication obligations under the REACH Regulation, as well as mandatory notification requirements for the SCIP database.

At the same time, the clearly defined date is August 1, 2026. From that date, imported articles containing the above substances at concentrations reaching or exceeding 0.1% must complete SCIP registration. For products that have not completed compliance procedures, known risks include customs clearance delays and a sales ban in the EU market.

The information provided also shows that this adjustment will directly affect the compliance path for Chinese amino acid exporters supplying the EU. The main products involved include cystine, tyrosine, and leucine, as well as related chelates and composite liquid formulations.

The impact does not stop at the export end

Companies supplying the EU directly will first face pressure to screen product categories

From an industry perspective, trading companies and export companies that supply the EU market directly will be affected first. Once the relevant substances are added to the SVHC Candidate List, companies can no longer handle shipments solely according to existing product names or conventional order procedures. Instead, they need to recheck whether their products involve L-cystine, L-tyrosine, DL-leucine, or related formulation forms. The main impacts involve product classification, preparation of compliance documents, pre-shipment confirmation, and the alignment of responsibilities with importers.

Processing and manufacturing stages need to reassess formulation and material information

For processing and manufacturing companies, the impact does not necessarily occur only at the point of final export. If products involve cystine, tyrosine, leucine, or their chelates and composite liquid formulations, companies need to pay attention to the presence of the relevant substances in their formulations and determine whether their concentrations will trigger notification obligations. At the business level, the main changes concern the review of material lists, internal compliance confirmation, and cooperation in providing external technical documents.

The alignment of responsibilities between importers and distribution channels will become more sensitive

It can be observed that importers and channel distributors are focused on the fact that the time requirement is already very close to actual business execution. From August 1, 2026, the relevant imported articles must complete SCIP registration. This means that the import side cannot rely solely on verbal statements from suppliers, but must pay closer attention to whether the notification has been completed, whether the information is consistent, and who will undertake the corresponding compliance actions. The main business risks involve customs clearance arrangements, inventory circulation, and the pace of market listing.

Supply-chain service providers and purchasers need to become involved in delivery arrangements earlier

For supply-chain service companies, purchasers, and coordination roles related to EU orders, this change will be transmitted to delivery lead times and communication mechanisms. Analysis indicates that all stages involving customs declaration, delivery scheduling, customer confirmation, and document coordination may require additional preparatory steps due to the SCIP notification obligation. What currently deserves greater attention is whether compliance actions will become a necessary condition before shipment and whether customers will request more complete substance information in advance.

Which practical issues should companies focus on now?

First confirm which products actually fall within the scope of this round of impacts

The first thing companies need to do is not to generalize that “all amino acid products are affected,” but to combine the three clearly identified substances and relevant product forms to verify whether their products supplied to the EU involve L-cystine, L-tyrosine, DL-leucine, or cystine-, tyrosine-, and leucine-related chelates and composite liquid formulations. This determination will directly affect whether they need to enter the SCIP preparation process.

Review time milestones and business milestones in the same schedule

August 1, 2026, is the clearly defined implementation date. For companies, the more practical question is whether orders, production, shipment, arrival at port, and customer receipt will cross this date. Analysis indicates that the proximity of the date means companies need to review regulatory requirements together with their existing delivery plans, rather than waiting until customs declaration or customer inquiries to begin preparations.

Customer communication must not stop at “being aware of the policy”

In EU supply scenarios, customers are more concerned with whether responsibilities have been implemented, whether documents are complete, and whether delivery will be obstructed. What currently deserves greater attention is that companies need to turn “the policy has changed” into specific communication covering “whether the product is involved, whether it reaches the threshold, whether SCIP is required, and who will complete the relevant actions.” In particular, consistency in information transmission between importers and suppliers may directly affect fulfillment arrangements.

Continue monitoring subsequent changes in official statements and implementation details

Although the substances have now been clearly added to the SVHC Candidate List and related SCIP obligations have been triggered, from a practical perspective companies still need to continue monitoring subsequent official statements, implementation interpretations, and supplementary requirements from customers. It can be observed that the policy signal has already been translated into clear compliance actions, but document formats, division of responsibilities, and business coordination methods during actual implementation still warrant continued follow-up.

This is more like a signal that the compliance chain is moving upstream

Analysis indicates that the significance of this information is not limited to the addition of three amino acid SVHC substances. More importantly, it moves compliance pressure further upstream from the product side to supply-chain information identification and notification implementation. For Chinese companies exporting to the EU, the impact is no longer an abstract regulatory change, but one that will affect order decisions, customer coordination, and delivery organization.

At the same time, judgment should remain measured. What has currently been confirmed is the addition to the list, the date, and the risks of non-compliance. The actual degree of impact on different companies will also depend on product structure, customer distribution, and whether the relevant substances reach the triggering conditions. It is more appropriate to understand this as a clearly defined compliance requirement that has entered the implementation phase, while its business-level impact still needs to be verified by companies on an order-by-order and product-category-by-product-category basis.

Short-term response should also be understood in the context of long-term requirements

Overall, the changes related to REACH and SCIP are first and foremost a compliance matter requiring a short-term response, because the date is clear and the risks of non-compliance already extend to customs clearance and market sales. From a longer-term perspective, however, they also send a clear signal: transparency of information concerning specific substances and the coordination of supply-chain responsibilities are becoming fundamental requirements that cannot be avoided in EU business.

Therefore, it is currently more appropriate to understand this information as “a rule change that has already occurred and requires immediate action,” as well as an industry development worth continuing to track. For the companies concerned, the key is not to magnify the impact, but to promptly complete the identification of affected products, document verification, and customer communication, and to genuinely integrate compliance actions into the EU supply process.

Basis of this article and directions for subsequent verification

This article was generated based on the information title, date of the event, and event summary provided by the user. The core information includes: the EU ECHA notice issued on its official website on July 23, 2026; the inclusion of L-cystine, L-tyrosine, and DL-leucine in the SVHC Candidate List (29th batch); the requirement for relevant imported articles to complete SCIP registration from August 1, 2026; and the risks of customs clearance delays and a market sales ban that may result from non-compliance.

In terms of the type of information, such content usually also needs to be continuously cross-checked against official announcements, corporate announcements, industry association information, authoritative media reports, and documents from standards organizations. Since the input information does not provide a specific official source link, this article does not include a specific link. Further attention is still required regarding the wording of the official text, changes in implementation interpretations, and actual business implementation requirements.